Fulvestrant+Abemaciclib With or Without Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: ER-Positive Breast Cancer|HER2-negative Breast Cancer
Interventions: OTHER: Fulvestrant Run-In|OTHER: No Fulvestrant Run-In
Sponsor: The Methodist Hospital Research Institute
Collaborators: Eli Lilly and Company